Published in J Clin Invest on April 06, 2009
Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol (2013) 3.38
Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science (2010) 2.77
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69
The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol (2010) 1.48
High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One (2010) 1.46
NK Cell Recognition of Candida glabrata through Binding of NKp46 and NCR1 to Fungal Ligands Epa1, Epa6, and Epa7. Cell Host Microbe (2016) 1.46
Mechanical stress downregulates MHC class I expression on human cancer cell membrane. PLoS One (2014) 1.41
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.34
Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol (2014) 1.27
Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunol Immunother (2013) 1.22
Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest (2012) 1.22
Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol (2013) 1.13
Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ (2013) 1.11
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One (2012) 1.08
The tumor microenvironment: a pitch for multiple players. Front Oncol (2013) 1.07
CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia (2011) 1.07
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J Immunol (2009) 1.04
Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One (2013) 1.02
Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother (2011) 0.99
Elucidating the mechanisms of influenza virus recognition by Ncr1. PLoS One (2012) 0.94
Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis (2012) 0.94
Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes. PLoS One (2013) 0.93
Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcoma. PLoS Pathog (2012) 0.93
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res (2010) 0.90
Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One (2009) 0.89
Natural killer cells in non-hematopoietic malignancies. Front Immunol (2012) 0.89
Leukocyte driven-decidual angiogenesis in early pregnancy. Cell Mol Immunol (2014) 0.88
Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology (2012) 0.87
Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun (2014) 0.87
TNF-α-dependent hematopoiesis following Bcl11b deletion in T cells restricts metastatic melanoma. J Immunol (2014) 0.86
Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest (2015) 0.86
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J Transl Med (2013) 0.85
CD11b(-)CD27(-) NK cells are associated with the progression of lung carcinoma. PLoS One (2013) 0.85
Natural killer cells as helper cells in dendritic cell cancer vaccines. Front Immunol (2015) 0.84
Increased Soluble CD155 in the Serum of Cancer Patients. PLoS One (2016) 0.82
Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time. Curr Oncol (2012) 0.82
Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Mol Cell Biol (2014) 0.82
Nicotinic receptor β2 determines NK cell-dependent metastasis in a murine model of metastatic lung cancer. PLoS One (2013) 0.82
Newtonian cell interactions shape natural killer cell education. Immunol Rev (2015) 0.81
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? J Immunol Res (2016) 0.81
Tumor cell recognition by γδ T lymphocytes: T-cell receptor vs. NK-cell receptors. Oncoimmunology (2013) 0.81
Identification of putative novel O-glycosylations in the NK killer receptor Ncr1 essential for its activity. Cell Discov (2015) 0.80
Human herpesviridae methods of natural killer cell evasion. Adv Virol (2012) 0.80
DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. Cancer Immunol Immunother (2014) 0.80
DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med (2015) 0.79
NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution. Oncoimmunology (2016) 0.79
NKG2D is a Key Receptor for Recognition of Bladder Cancer Cells by IL-2-Activated NK Cells and BCG Promotes NK Cell Activation. Front Immunol (2015) 0.79
The expression of the beta cell-derived autoimmune ligand for the killer receptor nkp46 is attenuated in type 2 diabetes. PLoS One (2013) 0.79
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Front Immunol (2016) 0.78
Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. Front Immunol (2016) 0.78
Super natural killer cells that target metastases in the tumor draining lymph nodes. Biomaterials (2015) 0.78
Expression and function of NKp46 W32R: the human homologous protein of mouse NKp46 W32R (Noé). Sci Rep (2017) 0.77
Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk. Oncoimmunology (2012) 0.77
NK Cells of Kidney Transplant Recipients Display an Activated Phenotype that Is Influenced by Immunosuppression and Pathological Staging. PLoS One (2015) 0.77
Intranodal interaction with dendritic cells dynamically regulates surface expression of the co-stimulatory receptor CD226 protein on murine T cells. J Biol Chem (2011) 0.77
An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget (2014) 0.77
Taming killer cells may halt diabetes progression. Nat Immunol (2010) 0.77
HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. Oncotarget (2015) 0.77
Critical roles of co-activation receptor DNAX accessory molecule-1 in natural killer cell immunity. Immunology (2015) 0.77
BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands. Oncotarget (2017) 0.76
Nonclassical NK cell education. Nat Immunol (2012) 0.76
Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing. Oncoimmunology (2016) 0.76
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol (2015) 0.76
SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling. Nat Immunol (2017) 0.76
Structural, mutational and biophysical studies reveal a canonical mode of molecular recognition between immune receptor TIGIT and nectin-2. Mol Immunol (2016) 0.75
Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells. Oncoimmunology (2016) 0.75
Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model. Evid Based Complement Alternat Med (2017) 0.75
NKG2D ligand expression in pediatric brain tumors. Cancer Biol Ther (2016) 0.75
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncoimmunology (2016) 0.75
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function. Oncotarget (2016) 0.75
IL12-mediated sensitizing of T-cell receptor-dependent and -independent tumor cell killing. Oncoimmunology (2016) 0.75
NK cells control breast cancer and related cancer stem cell hematological spread. Oncoimmunology (2017) 0.75
Cd226(-/-) natural killer cells fail to establish stable contacts with cancer cells and show impaired control of tumor metastasis in vivo. Oncoimmunology (2017) 0.75
Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis. Oncoimmunology (2017) 0.75
Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression. Sci Rep (2017) 0.75
Biology of natural killer cells. Adv Immunol (1989) 14.77
NK cell recognition. Annu Rev Immunol (2005) 14.40
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol (2006) 5.00
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood (2005) 3.99
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity (2005) 3.14
In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A (2000) 2.76
The role of natural killer cells in innate resistance to infection. Curr Opin Immunol (1993) 2.42
The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer (2003) 2.28
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule. Blood (1998) 1.94
Transgenic mouse model for skin malignant melanoma. Oncogene (1998) 1.90
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res (2004) 1.87
The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol (2000) 1.82
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res (2007) 1.70
Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med (2008) 1.63
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res (2007) 1.45
Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol (2009) 1.44
Natural killer cell activation in mice and men: different triggers for similar weapons? Nat Immunol (2002) 1.44
Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci (1989) 1.44
Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood (2005) 1.39
Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood (2004) 1.39
Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res (2002) 1.24
HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol (2002) 1.08
Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells. Cancer Res (2004) 1.06
Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol (2000) 1.03
Pathways to melanoma development: lessons from the mouse. J Invest Dermatol (2002) 1.02
NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol (2005) 1.01
Establishment of cell lines of uveal melanoma. Methodology and characteristics. Invest Ophthalmol Vis Sci (1984) 0.99
Expression of ligands to NKp46 in benign and malignant melanocytes. J Invest Dermatol (2007) 0.93
The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin Cancer Res (2006) 0.88
Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients. Cancer Immunol Immunother (1994) 0.81
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
TERT promoter mutations in familial and sporadic melanoma. Science (2013) 7.82
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Genome sequencing and analysis of Aspergillus oryzae. Nature (2005) 5.47
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood (2011) 4.57
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 4.36
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol (2007) 4.12
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol (2005) 3.81
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 3.41
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med (2014) 3.08
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
Periurethral injection of autologous adipose-derived regenerative cells for the treatment of male stress urinary incontinence: Report of three initial cases. Int J Urol (2012) 2.88
Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science (2010) 2.77
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol (2012) 2.68
A Role for cis Interaction between the Inhibitory Ly49A receptor and MHC class I for natural killer cell education. Immunity (2009) 2.62
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle (2011) 2.43
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol (2005) 2.35
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood (2008) 2.34
Effects of a programme of interventions on regional comprehensive palliative care for patients with cancer: a mixed-methods study. Lancet Oncol (2013) 2.34
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature (2007) 2.26
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood (2008) 2.24
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 2.21
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood (2002) 2.20
GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity (2003) 2.15
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother (2004) 2.12
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
What is a natural killer cell? Nat Immunol (2002) 2.11
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res (2012) 2.09
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Genomic analysis of homotypic vacuole fusion. Mol Biol Cell (2002) 2.06
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 2.03
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol (2002) 2.02
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med (2003) 2.01
Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol (2013) 2.00
NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol (2009) 2.00
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood (2004) 1.95
A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood (2012) 1.92
Surface NK receptors and their ligands on tumor cells. Semin Immunol (2006) 1.92